Establishment of a tear protein biomarker panel differentiating between Graves’ disease with or without orbitopathy

Cecilie Aass, Ingrid Norheim, Erik Fink Eriksen, Ellen Charlotte Børnick, Per Medbøe Thorsby and Milaim Pepaj

PLOS ONE, 2017, vol. 12, issue 4, 1-12

Abstract: Background: Graves’ orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves’ disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted. Patients and methods: The aim of the present study was to evaluate tear levels of LYZ, LACRT and AZGP1 in GD patients with or without GO, as possible biomarkers for GO. Tear samples were collected from GD patients with moderate-to-severe GO (n = 21) and no clinical signs of GO (n = 21). Additionally, 18 GD patients with mild GO and 9 patients without GO were included in a further part of the study. Results: Tear levels of LYZ (p

Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175274 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 75274&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0175274

DOI: 10.1371/journal.pone.0175274

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().